(1) General Practice Research Database, Medicines and Healthcare products Regulatory Agency, Buckingham Palace Road, London, SW1W 9SZ, UK;(2) Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands
Abstract:
Introduction
Recent studies suggesting an increased cancer risk with glucose-lowering agents have received widespread publicity. The objectives
of this study were to evaluate the comparability in underlying cancer risk and patterns of cancer risk over time with different
glucose-lowering agents.